We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc | NASDAQ:AUPH | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 1.18% | 5.16 | 5.10 | 5.16 | 5.18 | 5.04 | 5.12 | 1,336,343 | 00:56:46 |
From May 2022 to May 2024
NEW YORK, May 20, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/aurinia-pharmaceuticals-inc-loss-submission-form/?id=27460&from=4
The lawsuit seeks to recover losses for shareholders who purchased Aurinia Pharmaceuticals Inc. between May 7, 2021 and February 25, 2022.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until June 14, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Aurinia Pharmaceuticals Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original content:https://www.prnewswire.com/news-releases/auph-shareholder-alert-jakubowitz-law-reminds-aurinia-pharmaceuticals-inc-shareholders-of-a-lead-plaintiff-deadline-of-june-14-2022-301551407.html
SOURCE Jakubowitz Law
Copyright 2022 PR Newswire
1 Year Aurinia Pharmaceuticals Chart |
1 Month Aurinia Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
